{"id":4396,"date":"2025-03-31T18:12:06","date_gmt":"2025-03-31T18:12:06","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/telithromycin-txt\/"},"modified":"2025-03-31T18:12:06","modified_gmt":"2025-03-31T18:12:06","slug":"telithromycin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/telithromycin-txt\/","title":{"rendered":"Telithromycin.txt"},"content":{"rendered":"

CLINICAL USE <\/H3>
\nAntibacterial agent

DOSE IN NORMAL RENAL FUNCTION <\/H3>800 mg daily

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :812<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :60\u201370<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : 12<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :1.9\u20133.9<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :2\u20133\/14.64

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>30\u201350 Dose as in normal renal function 10\u201330 600 mg daily (given as 800 mg\/400 mg alternating days)
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : 600 mg daily (given as 800 mg\/400 mg alternating days)

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unknown dialysability. Dose as in GFR <10 mL\/min <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Dialysed. Dose as in GFR <10 mL\/min . (Give 800 mg dose after dialysis sessios)
  • HDF\/high flux &nbsp :Dialysed. Dose as in GFR <10 mL\/min . (Give 800 mg dose after dialysis session)
  • CAV\/VVHD &nbsp &nbsp &nbsp:Dialysed. Dose as in GFR 10 to 20 mL\/min

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Antibacterials: concentration reduced by rifampicin \u2013 avoid during and for 2 weeks after rifampicin therapy\n
  • Antidepressants: concentration reduced by St John\u2019s wort \u2013 avoid during and for 2 weeks after St John\u2019s wort therapy\n
  • Anti-epileptics: concentration reduced by carbamazepine, phenytoin, phenobarbital and primidone \u2013 avoid during and for 2 weeks after treatment\n
  • Antifungals: avoid in combination with ketoconazole in severe renal and hepatic impairment\n
  • Antipsychotics: increased risk of ventricular arrhythmias with pimozide \u2013 avoid concomitant use\n
  • Antivirals: avoid concomitant use with amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir and tipranavir in severe renal and hepatic impairmentAnxiolytics and hypnotics: inhibits metabolism of midazolam (increased sedation)\n
  • Ciclosporin: possibly increased ciclosporin levels\n
  • Diuretics: increased eplerenone concentration \u2013 avoid concomitant useTelithromycin and ergot derivatives should not be co-administered due to possibility of ergotismIvabradine: possibly increased ivabradine concentration \u2013 avoid concomitant useLipid-regulating drugs: increased risk of myopathy with atorvastatin and simvastatin \u2013 avoid concomitant useSirolimus: increased sirolimus levels \u2013 avoid concomitant use\n
  • Tacrolimus: possibly increased tacrolimus levels

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>Do not give to people at risk of QT interval prolongation due to its potential to prolong the QT intervalOral bioavailability is approximately 57% after a single dose of 800 mgIn patients with renal and hepatic impairment the dose should be reduced to 400 mg dailyMonitor for signs of liver toxicity AUC increased 2-fold if GFR<30 mL\/min .
    \n","protected":false},"excerpt":{"rendered":"

    CLINICAL USE Antibacterial agent DOSE IN NORMAL RENAL FUNCTION 800<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4396","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4396"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4396\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}